Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy.

Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW.

Brachytherapy. 2013 May-Jun;12(3):204-9. doi: 10.1016/j.brachy.2011.12.013. Epub 2012 Jun 5.

2.

Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA <or=10, and clinically localized prostate cancer.

Cheng GC, Chen MH, Whittington R, Malkowicz SB, Schnall MD, Tomaszewski JE, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):64-70.

PMID:
12504037
3.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
4.

Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer.

Hegde JV, Chen MH, Mulkern RV, Fennessy FM, D'Amico AV, Tempany CM.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):e101-7. doi: 10.1016/j.ijrobp.2012.08.032. Epub 2012 Oct 3.

6.

The role of endorectal coil MRI in patient selection and treatment planning for prostate seed implants.

Clarke DH, Banks SJ, Wiederhorn AR, Klousia JW, Lissy JM, Miller M, Able AM, Artiles C, Hindle WV, Blair DN, Houk RR, Sheridan MJ.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):903-10.

PMID:
11958882
7.
8.

Accuracy of endorectal magnetic resonance/transrectal ultrasound fusion for detection of prostate cancer during brachytherapy.

Bubley GJ, Bloch BN, Vazquez C, Genega E, Holupka E, Rofsky N, Kaplan I.

Urology. 2013 Jun;81(6):1284-9. doi: 10.1016/j.urology.2012.12.051. Epub 2013 Mar 13.

PMID:
23490527
9.

Commentary on "Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy".

Wallner KE.

Brachytherapy. 2013 May-Jun;12(3):202. doi: 10.1016/j.brachy.2013.01.001. Epub 2013 Feb 12. No abstract available.

PMID:
23415049
10.

Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy.

Riaz N, Afaq A, Akin O, Pei X, Kollmeier MA, Cox B, Hricak H, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):707-11. doi: 10.1016/j.ijrobp.2012.01.009. Epub 2012 Mar 15.

PMID:
22425220
11.

The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer.

D'Amico AV, Whittington R, Schnall M, Malkowicz SB, Tomaszewski JE, Schultz D, Wein A.

Cancer. 1995 May 1;75(9):2368-72.

12.

Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer.

Nguyen PL, Whittington R, Koo S, Schultz D, Cote KB, Loffredo M, Tempany CM, Titelbaum DS, Schnall MD, Renshaw AA, Tomaszewski JE, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):400-5.

PMID:
15145155
13.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
14.

The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy.

Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman DW, Sargent DJ, Bostwick DG.

Cancer. 1999 Jun 15;85(12):2630-7.

PMID:
10375112
15.

Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure.

D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A.

Urology. 1997 Mar;49(3A Suppl):23-30. Review.

PMID:
9123732
16.

A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.

D'Amico AV, Whittington R, Malkowicz SB, Schnall M, Tomaszewski J, Schultz D, Kao G, VanArsdalen K, Wein A.

Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):293-302.

PMID:
7928457
17.

Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.

Kestin LL, Goldstein NS, Vicini FA, Martinez AA.

J Urol. 2002 Nov;168(5):1994-9.

PMID:
12394693
18.
19.

Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8.

Manoharan M, Bird VG, Kim SS, Civantos F, Soloway MS.

BJU Int. 2003 Oct;92(6):539-44.

20.

Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.

D'amico AV, Tempany CM, Schultz D, Cormack RA, Hurwitz M, Beard C, Albert M, Kooy H, Jolesz F, Richie JP.

Urology. 2003 Dec;62(6):1063-7.

PMID:
14665356
Items per page

Supplemental Content

Write to the Help Desk